Therapeutic role of systematic retroperitoneal lymphadenectomy in endometrial cancer - 25/03/15
Abstract |
Objective |
The purpose of this study was to evaluate the therapeutic role of systematic retroperitoneal lymphadenectomy in patients with endometrial cancer.
Methods |
From December2003 to December2008, 349eligible patients who underwent surgical staging procedures at primary treatment were retrospectively analyzed: systematic lymphadenectomy group (n = 246) and no-lymphadenectomy group (n = 103). Survival was analyzed using Kaplan-Meier method and Cox proportional hazards model.
Results |
Overall, patients who underwent lymphadenectomy improved 5-year disease-free survival (89.0% versus 80.7%, P = 0.019) and overall survival (92.8% versus 81.5%, P = 0.001) compared to those who did not undergo lymphadenectomy. Overall survival was not related to lymphadenectomy in 212low-risk patients (93.1% versus 84.6%, P = 0.176). However, this association was found in 137patients with intermediate and high-risk (86.2% versus 73.3%, P = 0.021). Multivariate Cox regression analysis showed that FIGO stage (P = 0.037) and lymphadenectomy (P = 0.023) were independent prognostic factors for overall survival.
Conclusions |
Systematic retroperitoneal lymphadenectomy has a potentially therapeutic role on survival in surgically staged patients with endometrial cancer.
Le texte complet de cet article est disponible en PDF.Key words : endometrial cancer, lymphadenectomy, prognosis
Plan
Vol 99 - N° 2
P. E10-E17 - février 2012 Retour au numéro
Article précédent
- SALTO: a randomized, multicenter study assessing octreotide LAR in inoperable bowel obstruction
- Guillemette Laval, Hubert Rousselot, Sophie Toussaint-Martel, Françoise Mayer, Éric Terrebonne, Éric François, Hédia Brixi, Thierry Nguyen, Isabelle Bourdeix, Ségolène Bisot-Locard, Laurent Zelek, for the SALTO study group
- First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer
- Julien Peron, Olivier Tredan, Isabelle Ray-Coquard, Thomas Bachelot, Sana Intidhar Labidi Galy, Bertrand Favier, Isabelle Treilleux, Jean-Paul Guastalla
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?